FDA approves Caplyta for relapse prevention in schizophrenia, adding long-term Phase III data showing a 63% reduction in relapse risk and reinforcing its role in sustained disease management.
Johnson & Johnson received FDA approval for its supplemental New Drug Application (NDA) for Caplyta (lumateperone)for the prevention of relapse in adults with schizophrenia.
Emerging Pharma Leaders nominations are now open!
Do you know someone who can make tough decisions that continue to face manufacturers? Are they destined to change the future of pharma?
Nominate a colleague with impressive leadership and career intentions – even yourself! – for the Pharmaceutical Executive 2026 Emerging Pharma Leaders Awards.
The decision is based on long-term Phase III data and reinforces the therapy’s role in addressing one of the most persistent challenges in schizophrenia management: maintaining stability and reducing the risk of recurrent episodes.1
Relapse remains a central concern in schizophrenia care, often leading to hospitalization, functional decline, and increased caregiver burden. Despite available treatments, a significant proportion of patients remain inadequately managed, with many experiencing repeated episodes over time. Against this backdrop, therapies that demonstrate durable efficacy and tolerability are increasingly prioritized in long-term treatment strategies.
The approval is supported by a Phase III, double-blind, randomized withdrawal study in which Caplyta significantly extended time to relapse compared with placebo over a 26-week period.2 Patients receiving the therapy experienced a 63% reduction in relapse risk, with 84% remaining relapse-free at six months. The study also showed a delay in time to all-cause treatment discontinuation, a key measure reflecting both efficacy and tolerability in real-world use.2
“Relapse can be one of the most disruptive aspects of schizophrenia, often undoing hard-won progress and increasing the risk of hospitalization,” said Christoph U. Correll, M.D., clinical professor of Psychiatry at the Zucker School of Medicine at Hofstra/Northwell. “These Phase III results, showing significantly longer time to relapse with 84% remaining relapse free over 6-months, provide clinicians with another tool that can offer long-term stability for people living with schizophrenia.”
Safety findings in the trial were consistent with the established profile of Caplyta, with no new safety signals identified. The most commonly reported adverse event was headache. Notably, the therapy has demonstrated a relatively favorable profile across weight, metabolic parameters, and extrapyramidal symptoms in prior studies, factors that are often associated with treatment discontinuation in antipsychotic therapy.2
While Caplyta’s exact mechanism of action is not fully understood, it is characterized by high serotonin 5-HT2A receptor occupancy and moderate dopamine D2 receptor activity, a profile that may contribute to its efficacy and tolerability balance. Long-term data from a 12-month open-label extension study further support its safety, with patients showing modest weight reduction and stable metabolic parameters over time.1
“People living with schizophrenia deserve treatment options that help support stability over time, not just symptom control in the short term,” said Celine Goldberger, MD, PhD, vice president, Global Medical Affairs, Neuroscience, Innovative Medicine, Johnson & Johnson. “This label update, backed by long-term Phase III data demonstrating a significant delay in time to relapse, reinforces our commitment to advancing evidence-based therapies to support each patient's individual needs.”
The label expansion builds on Caplyta’s existing approvals across schizophrenia, bipolar depression, and major depressive disorder as an adjunctive therapy, positioning it as a multi-indication asset within Johnson & Johnson’s neuroscience portfolio.1
Caplyta’s new approval also reflects broader industry efforts to differentiate antipsychotic treatments not only on efficacy, but on long-term outcomes such as relapse prevention, adherence, and tolerability.
In an exclusive
With schizophrenia continuing to carry significant clinical and economic burden, the addition of relapse prevention data to Caplyta’s label may influence treatment decisions, particularly for clinicians seeking options that balance sustained efficacy with a manageable side effect profile in chronic care settings.
